- Home
- DLTR vs MRNA Comparison
DLTR vs MRNA Comparison
Compare DLTR & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DLTR | MRNA |
|---|---|---|
| Founded | 1986 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Department/Specialty Retail Stores | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.2B | 26.7B |
| IPO Year | 1996 | 2018 |
Fundamental Metrics
Financial Performance| Metric | DLTR | MRNA |
|---|---|---|
| Price | $124.73 | $78.39 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 18 | 12 |
| Target Price | ★ $123.35 | $34.27 |
| AVG Volume (30 Days) | 3.3M | ★ 8.3M |
| Earning Date | 06-03-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 144.33 | 21.77 |
| EPS | ★ 1.76 | N/A |
| Revenue | ★ $19,411,800,000.00 | $19,263,000,000.00 |
| Revenue This Year | $8.48 | $9.36 |
| Revenue Next Year | $5.90 | $15.43 |
| P/E Ratio | $70.48 | ★ N/A |
| Revenue Growth | ★ 10.43 | 4.29 |
| 52 Week Low | $84.71 | $22.28 |
| 52 Week High | $142.40 | $81.40 |
Technical Indicators
Market Signals| Indicator | DLTR | MRNA |
|---|---|---|
| Relative Strength Index (RSI) | 67.71 | 78.48 |
| Support Level | $117.54 | $45.69 |
| Resistance Level | $132.48 | N/A |
| Average True Range (ATR) | 4.33 | 5.37 |
| MACD | 0.68 | 2.17 |
| Stochastic Oscillator | 97.69 | 93.28 |
Price Performance
Historical ComparisonAbout DLTR Dollar Tree Inc.
Founded in 1986, Dollar Tree operates almost 9,000 small-box discount stores across the United States and Canada, offering roughly 85% of its merchandise under $2. The chain targets value-conscious suburban and urban shoppers with a mix of consumables (49% of sales), variety (45%), and seasonal goods (6%). In fiscal 2025, Dollar Tree generated over $19 billion in sales, through its multi-price strategy, higher-margin discretionary assortments, and private-label products that account for nearly one-third of sales.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.